Prescription Costs | sciencenewsnet.in

Breaking News

Glaucoma Research Foundation establishes Strategic Advisory Council

1 in 5 milk samples from grocery stores test positive for bird flu. Why the FDA says it’s still safe to drink

‘Fallout’ success: video game nostalgia spans multiple media, explains expert

Scientists are shaking up lithium extraction with a different kind of chemistry

ORNL’s Curran named Fellow of SAE, ASME

Computer Scientists Unveil Novel Attacks on Cybersecurity

Interplay between mesenchymal stem cells and macrophages: Promoting bone tissue repair

Mesenchymal stem cells and their derived exosomes for the treatment of COVID-19

Biological scaffold as potential platforms for stem cells: Current development and applications in wound healing

Effects of high glucose and severe hypoxia on the biological behavior of mesenchymal stem cells at various passages

27 Apr, 2024

Low-cost generic drug programs have large gaps in coverage for core evidence-based CVD medications

September 4, 2023 sarah JonasResearch Results

A cross-sectional study of 19 low-cost generic programs (LCGPs) found that their medication coverage for six cardiovascular diseases (CVD) varied significantly between programs. Of all analyzed programs, Mark Cuban Cost Plus Drug Company demonstrated the most comprehensive coverage for all diseases included in the study. The findings are published in Annals of Internal Medicine.

ACR Co-Authors Amicus Brief in Support of North Dakota Regulating PBM Industry

July 6, 2021 sarah JonasPolicy

The Alliance for Transparent & Affordable Prescriptions (ATAP), the Community Oncology Alliance (COA), and American Pharmacies filed an amicus brief with the 8th Circuit Court of Appeals in support of North Dakota’s efforts to regulate practices of pharmacy benefit managers (PBMs).